Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET
Rhea-AI Summary
Agios (Nasdaq: AGIO) will hold a conference call and live webcast on April 29, 2026 at 8:00 a.m. ET to report first quarter 2026 financial results and business highlights.
The live webcast will be available on the company’s Investors site under Events & Presentations, and a replay will be posted approximately two hours after the event.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – AGIO
On the day this news was published, AGIO declined 1.14%, reflecting a mild negative market reaction. This price movement removed approximately $24M from the company's valuation, bringing the market cap to $2.06B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AGIO is up 2.95% ahead of its earnings call notice. Peers show mixed moves: DNLI +9.13%, IRON +2.69%, APGE +2.00%, FOLD +0.07%, while TVTX is down 0.81%, pointing to stock-specific drivers rather than a clean sector-wide move.
Previous Conferences,earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 26 | Earnings call notice | Neutral | +1.0% | Announced Q4 and full-year 2025 results call with webcast replay details. |
| Oct 16 | Earnings call notice | Neutral | +0.3% | Set date and time for Q3 2025 financial results call and webcast. |
| Jul 14 | Earnings call notice | Neutral | +0.5% | Announced Q2 2025 financial results conference call and webcast schedule. |
| Apr 17 | Earnings call notice | Neutral | +1.9% | Scheduled Q1 2025 financial results webcast and business update call. |
| Feb 06 | Earnings call notice | Neutral | +0.1% | Outlined timing for Q4 and full-year 2024 financial results webcast. |
Scheduling earnings calls has historically coincided with small, generally positive price moves.
Over the past year, AGIO has repeatedly issued "conference call and webcast" notices for quarterly and annual results, all tagged as conferences,earnings. These events, from Feb 13, 2025 through Feb 12, 2026, consistently outlined timing and access details, with modest positive next-day price reactions between 0.12% and 1.92%. Today’s Q1 2026 call announcement follows the same established communications pattern.
Historical Comparison
Past earnings call notices for AGIO with conferences,earnings tags saw average next-day moves of 0.77%, typically small and positive. Today’s Q1 2026 call announcement fits this pattern of modest, communication-driven stock reactions.
AGIO has maintained a consistent cadence of earnings call announcements from full-year 2024 through successive 2025 quarters, signaling ongoing transparency around results and business updates.
Regulatory & Risk Context
AGIO has an effective automatic shelf registration on Form S-3ASR filed on 2026-02-12, allowing the company to offer various securities over time. Any proceeds may be used for general corporate purposes, including R&D, clinical and commercialization spend, potential acquisitions or investments, and possible debt repayment or refinancing.
Market Pulse Summary
This announcement schedules AGIO’s Q1 2026 financial results conference call for April 29, 2026 at 8:00 a.m. ET, with a webcast and replay via the investor website. Historically, similar conferences,earnings notices have led to small, generally positive price moves. Investors may focus on upcoming disclosures about revenue trends, R&D progress, and use of the effective Form S-3ASR shelf registration when evaluating future developments.
AI-generated analysis. Not financial advice.
CAMBRIDGE, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Wednesday, April 29, 2026, at 8:00 a.m. ET to report its first quarter 2026 financial results and business highlights.
The live webcast will be accessible on the Investors section of the company’s website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be available on the company’s website approximately two hours after the event.
About Agios: Fueled by Connections to Transform Rare Diseases™
At Agios, our vision is to redefine the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities – collaborating to develop and deliver innovative medicines that have the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve. Agios is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. To learn more, visit www.agios.com and follow us on LinkedIn and X.
Available Information about Agios
To achieve broad dissemination, Agios may disclose information to the public through a variety of disclosure channels including press releases, SEC filings, and public conference calls and webcasts. Some of the information distributed through these disclosure channels may be considered material information. Investors and others should note that Agios plans to use its website (www.agios.com) as a distribution channel to announce and give notice of Agios’ upcoming events and presentations (including, but not limited to, presentations at medical or healthcare conferences). Such information, which may be deemed material, will be available on the Investors section of the company’s website under the “Events & Presentations” tab. In addition, you may sign up to automatically receive email alerts about Agios’ upcoming events and presentations (“Calendar Alerts”) by visiting the “Email Alerts” option under the “IR Resources” tab of the Investors section of the company’s website and submitting your email address.
Contacts:
Investor Contact
Morgan Sanford, Vice President, Investor Relations
Agios Pharmaceuticals
morgan.sanford@agios.com
Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
eamonn.nolan@agios.com
